A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment With DIO-902 [DiObex] or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-502)

Trial Profile

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment With DIO-902 [DiObex] or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-502)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Atorvastatin; DIO 902
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors DiObex
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Nov 2008 Status changed from recruiting to discontinued, as reported in ClinicalTrials.gov record.
    • 05 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top